# FHND9041 Versus Afatinib for Non-small Cell Lung Cancer

> **NCT06759857** · PHASE3 · ENROLLING_BY_INVITATION · sponsor: **Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.** · enrollment: 350 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** FHND9041
- **DRUG:** Afatinib

## Key facts

- **NCT ID:** NCT06759857
- **Lead sponsor:** Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2021-08-01
- **Primary completion:** 2025-03-04
- **Final completion:** 2025-05-01
- **Target enrollment:** 350 (ESTIMATED)
- **Last updated:** 2025-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06759857

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06759857, "FHND9041 Versus Afatinib for Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06759857. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*